Lancet Robotics Secures Series A Funding Led by CICC Capital to Accelerate Multi-Specialty Surgical Robot Commercialization and Global Expansion

Shenzhen Lancet Robot Co., Ltd. (hereinafter referred to as “Lancet Robot”) recently announced the completion of its Series A financing round, raising tens of millions of RMB with CICC Capital Operation Co., Ltd. as the lead investor. The funds from this round will be used to accelerate the industrialization and global market expansion of its multi-specialty surgical robot products, expand production capacity for surgical robots, and further consolidate the company’s leadership position in the field of surgical robotics.

Shenzhen Lancet Robot Co., Ltd. is committed to providing hospitals with end-to-end AI-assisted surgical solutions. The company’s founder, Huang Zhijun, graduated from the University of Science and Technology of China and Tsinghua University. With over a decade of deep engagement in the intelligent healthcare sector, he possesses profound industry insights and extensive experience in product commercialization.

After years of deep industry engagement and technological accumulation, the company has established a comprehensive portfolio of surgical robotic systems, covering multiple clinical fields including joint replacement, spinal surgery, dental implantology, neurosurgery, and vascular intervention. To date, the company has obtained three Class III medical device registration certificates, two Class II medical device registration certificates, and one U.S. FDA registration certificate, along with numerous honors and recognitions. Meanwhile, several of its surgical robotic products have entered the registration phase with China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).

Through independent research and development, Lancet Robot has achieved full domestication of surgical robots in terms of algorithms, manufacturing processes, and core components, gradually realizing the substitution of imported surgical robots with domestically produced ones. By empowering primary care hospitals with cost-effective intelligent equipment, it aims to make high-quality medical services accessible to every healthcare institution and patient group in need.

Currently, Lancet Robot’s products have been widely adopted in dozens of hospitals. In addition to traditional top-tier (Grade A tertiary) hospitals, its customer base has expanded to include county-level and municipal primary-care hospitals as well as private specialized hospitals. The significant reduction in the end-user price of surgical robots has made robot-assisted surgery increasingly accessible at primary-care hospitals.

Co-establishing a Clinical Application Training Base for Robotics with a Municipal-Level Private Orthopedic Specialty Hospital

As one of the first Chinese surgical robot manufacturers to obtain U.S. FDA registration, Lancet Robot is actively expanding its overseas presence. The company’s primary international customer base spans markets in South America, Southeast Asia, South Asia, and Eastern Europe. It has secured over 20 overseas orders and achieved commercial installation of multiple surgical robots at overseas clinical centers.

Huang Zhijun, Founder of Lancet RobotHe stated, “We are deeply grateful for CICC Capital’s trust in Lancet Robot. Surgical robots are primarily used to assist physicians in performing precise surgical procedures. Leveraging advantages such as intelligence, minimally invasive techniques, visualization, and remote operation, they can address clinical pain points for doctors, patients, and hospitals, and are poised to become commonplace tools in minimally invasive surgery in the future.”

“Over the past few years, the company has achieved innovative R&D breakthroughs in multiple surgical robot models. Following regulatory approval, we rapidly commercialized our products and are now accelerating our expansion into overseas markets. By leveraging domestically developed core components, we aim to empower a broader range of primary-care hospitals and patients with intelligent medical devices, striving to become a benchmark enterprise in the field of surgical robotics. This financing round will help us accelerate the development of new products, further expand production capacity, and promote global market expansion, thereby benefiting more patients and hospitals.”

Dr. Nie Feilong, Deputy General Manager of CICC Capital and Co-Head of Healthcare at Chuanhe Fundstated: “Our team has actively responded to CICC Capital’s mandate to ‘invest early, invest in small enterprises, and invest in hard technology.’ We are delighted to participate in the Series A financing of Lancet Robot. Lancet Robot’s technological innovations and product portfolio in the field of surgical robotics are impressive. The company’s products have demonstrated their capability as high-precision, low-radiation, and highly safe minimally invasive surgical solutions in clinical applications, providing patients with more precise, minimally invasive, and intelligent treatment options. We look forward to collaborating with Lancet Robot to jointly promote the high-quality development of surgical robotics technology and enhance the quality of medical services.”

Shenzhen Lancet Robot Co., Ltd., established in 2018, is a national high-tech enterprise specializing in medical surgical robots with deep strategic layouts across multiple premium surgical sectors, including joint replacement, spinal surgery, dental implantology, neurosurgery, and vascular intervention. The core members of its R&D team are predominantly graduates of prestigious domestic and international universities in science, engineering, and clinical medicine, possessing strong expertise in the integration of medicine and engineering as well as robust technical capabilities. The company has established stable and efficient research and innovation platforms that integrate industry, academia, research, and clinical practice in collaboration with professional institutions such as Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School) and The Second Affiliated Hospital of Zhejiang University School of Medicine. Committed to providing hospitals with comprehensive end-to-end solutions, the company offers AI-assisted diagnosis, personalized surgical planning, surgical navigation robot systems, and postoperative assessment.

CICC Capital is the private equity investment business operating platform of China International Capital Corporation Limited (“CICC”). It manages CICC’s onshore and offshore private equity investment businesses and has developed into one of China’s leading private equity investment management institutions. Currently, the funds managed by CICC Capital cover a range of types, including RMB corporate equity investment funds, funds of funds (FOFs), infrastructure funds, and USD corporate equity investment funds.